About OJO | Search | Ahead of print | Current Issue | Archives | Author Instructions | Reviewer Guidelines | Online submissionLogin 
Oman Journal of Ophthalmology Oman Journal of Ophthalmology
  Editorial Board | Subscribe | Advertise | Contact
https://www.omanophthalmicsociety.org/ Users Online: 601  Wide layoutNarrow layoutFull screen layout Home Print this page  Email this page Small font size Default font size Increase font size


 
 Table of Contents    
LETTER TO THE EDITOR
Year : 2012  |  Volume : 5  |  Issue : 1  |  Page : 68  

Intravitreal bevacizumab and diabetic papillopathy with macular edema


1 Sanitation Medical Academic Center, Bangkok, Thailand
2 Wiwanitkit House, Bangkhae, Bangkok, Thailand

Date of Web Publication7-Apr-2012

Correspondence Address:
Beuy Joob
Sanitation Medical Academic Center, Bangkok
Thailand
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0974-620X.94797

Rights and Permissions

How to cite this article:
Joob B, Wiwanitkit V. Intravitreal bevacizumab and diabetic papillopathy with macular edema. Oman J Ophthalmol 2012;5:68

How to cite this URL:
Joob B, Wiwanitkit V. Intravitreal bevacizumab and diabetic papillopathy with macular edema. Oman J Ophthalmol [serial online] 2012 [cited 2019 Oct 16];5:68. Available from: http://www.ojoonline.org/text.asp?2012/5/1/68/94797

Sir,

The recent publication on intravitreal bevacizumab and diabetic papillopathy with macular edema is very interesting. [1] Al-Hinai et al., conclude that "bevacizumab is a useful treatment in diabetic papillopathy by shortening the duration of the course of the disease". [1] It might seem that this treatment is effective. However, there are many things to be discussed. Experience of the practitioner is very important and there are some reports on complications of this practice. [2],[3] The observation on systemic change corresponding to the use of bevacizumab is also required. [4] Finally, although bevacizuman is more effective than simple triamcinolone acetonide, [5] the question of cost needs to be researched.

 
   References Top

1.Al-Hinai AS, Al-Abri MS, Al-Hajri RH. Diabetic papillopathy with macular edema treated with intravitreal bevacizumab. Oman J Ophthalmol 2011;4:135-8.  Back to cited text no. 1
  Medknow Journal  
2.Arevalo JF, Sanchez JG, Saldarriaga L, Berrocal MH, Fromow-Guerra J, Morales-Canton V, et al.; Pan American Collaborative Retina Study Group. Retinal detachment after bevacizumab. Ophthalmology 2011;118:2304.e3-7.  Back to cited text no. 2
[PUBMED]  [FULLTEXT]  
3.Jamrozy-Witkowska A, Kowalska K, Jankowska-Lech I, Terelak-Borys B, Nowosielska A, Grabska-Liberek I. Complications of intravitreal injections-Own experience. Klin Oczna 2011;113:127-31.  Back to cited text no. 3
[PUBMED]    
4.Matsuyama K, Ogata N, Matsuoka M, Wada M, Nishimura T, Takahashi K. Source Effects of intravitreally injected bevacizumab on vascular endothelial growth factor in fellow eyes. J Ocul Pharmacol Ther 2011;27:379-83.  Back to cited text no. 4
[PUBMED]  [FULLTEXT]  
5.Song JH, Lee JJ, Lee SJ. Comparison of the short-term effects of intravitreal triamcinolone acetonide and bevacizumab injection for diabetic macular edema. Korean J Ophthalmol 2011;25:156-60.  Back to cited text no. 5
[PUBMED]  [FULLTEXT]  




 

Top
   
 
  Search
 
  
    Similar in PUBMED
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this article
    References

 Article Access Statistics
    Viewed1298    
    Printed79    
    Emailed0    
    PDF Downloaded199    
    Comments [Add]    

Recommend this journal